Unlocking novel approaches for the treatment of age-related diseases

Crossbeta Biosciences is a biotech company that has developed an innovative technology to generate stable oligomers for drug discovery and development in disease areas characterized by the presence of misfolded proteins, such as Alzheimer’s, Parkinson’s, Huntington’s disease and ALS. Crossbeta’s unique stable oligomers maintain their biopathological properties for the screening of oligomer-specific therapeutics and for the development of biomarker and diagnostic assays.


Learn more about the high value opportunities Crossbeta Biosciences offers our stakeholders.

Learn more


Strong partnerships are key to our success. Are you also interested in a collaboration?

Learn more


Have a look to see at which congresses you can meet us.

June 19-22 2017 BIO International Convention San Diego, USA
July 16-20 2017 AAIC London, England